NKARTA INC has a total of 11 patent applications. Its first patent ever was published in 2019. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and Australia. Its main competitors in its focus markets biotechnology and pharmaceuticals are CHO PHARMA USA INC, ARCELLX INC and ANGIEX INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 5 | |
#2 | United States | 3 | |
#3 | Australia | 1 | |
#4 | Canada | 1 | |
#5 | EPO (European Patent Office) | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Chan Ivan | 8 |
#2 | Guo Chao | 7 |
#3 | Trager James Barnaby | 6 |
#4 | Tohmé Mira | 6 |
#5 | Trager James | 5 |
#6 | Buren Luxuan Guo | 5 |
#7 | Lazetic Alexandra Leida Liana | 5 |
#8 | Li Guangnan | 2 |
#9 | Lazetic Alexandra | 2 |
#10 | Liu Daofeng | 2 |
Publication | Filing date | Title |
---|---|---|
WO2021021907A1 | Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells | |
WO2020247392A1 | Combinations of engineered natural killer cells and engineered t cells for immunotherapy | |
AU2020232691A1 | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy | |
WO2020112563A1 | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy | |
CA3112195A1 | Natural killer cell compositions and immunotherapy methods for treating tumors |